NCT05183243View on ClinicalTrials.gov

GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results

PHASE1RecruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

February 20, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

February 20, 2025

Conditions
Advanced Solid TumorNon-Small Cell Lung CancerPancreatic CancerColorectal CancerHead and Neck Neoplasm
Interventions
DRUG

GH21 Capsule

GH21 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.

Trial Locations (9)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Science, Beijing

100143

RECRUITING

Beijing University Cancer Hospital, Beijing

210008

RECRUITING

Nanjing Drum Tower Hospital, Nanjing

230000

RECRUITING

The Second Hospital of Anhui Medical University, Hefei

317099

RECRUITING

Taizhou Hospital of Zhejiang Province, Linhai

450000

RECRUITING

Henan Cancer Hospital, Zhengzhou

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Unknown

RECRUITING

Chongqing Cancer Hospital, Chongqing

RECRUITING

The First Affiliated Hospital of Zhejiang University, Hangzhou

All Listed Sponsors
lead

Suzhou Genhouse Bio Co., Ltd.

OTHER